Stemgent Completes Acquisition of Asterand plc's Human Tissue Business

Published: Aug 01, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stemgent, Inc. announced today that it has completed the acquisition of Asterand Plc’s Human Tissue Business for $9 million. Asterand provides a set of high quality, human-tissue based tools for drug and drug target discovery that is highly complementary to Stemgent’s growing portfolio of innovative research products and services to advance cellular reprograming and stem cell research.

Back to news